Washington, D.C. 20549


Form 8-K


Current Report 


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report   (Date of earliest event reported):   April 1, 2019



(Exact name of registrant as specified in its charter)






(State or Other Jurisdiction of Incorporation)

(Commission File


(I.R.S. Employer Identification Number)


3020 Callan Road, San Diego, California 92121

(Address of principal executive offices, with zip code)


(858) 458-0900

(Registrant's telephone number, including area code)



(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):




    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)




    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)




    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))




    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is a n emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).


Emerging growth company

If an emerging growth company, indi c a te by check mark if the registrant has elected not to use the e x tended transition period for complying with any new or re v ised financial accounting standards pro v ided pursuant to Section 13(a) of the E x change Act.









Item 2.02 Results of Operations and Financial Condition


On April 1, 2019, Cytori Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2018. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.


The information disclosed under this Item 2.02 in this report, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.



Item 9.01 Financial Statements and Exhibits


(d) Exhibits


Exhibit No.      



Cytori Therapeutics, Inc. Press Release, dated April 1, 2019









Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.









Date:  April 1, 2019

By: /s/ Gary Titus


Gary Titus


Chief Financial Officer






Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Cytori Therapeutics Charts.
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Cytori Therapeutics Charts.